Candid Therapeutics Acquired by Rallybio | Healthcare M&A Deal

Rallybio has completed the acquisition of Candid Therapeutics, a healthcare services other business in Connecticut, for $505.5 million. Rallybio acquisitions focus on expanding healthcare services other capabilities, with Candid Therapeutics operating in the biopharma and therapeutic development space. The merger acquisition supports Rallybio’s strategic acquisition agenda and strengthens its healthcare M&A footprint through CT acquisitions in New Haven. This strategic acquisition is structured as a merger acquisition with an announced status and an over-$100M deal size, with deal documentation filed as an S-4/A registration statement.